We recommend using a newer internet browser, such as Google Chrome or Microsoft Edge, to optimize your browsing experience.

Skip to main content

Search

Press to close the select your country window or navigate to it's content

Find more information about Teva in your location, or contact a local representative on our local sites

North America

Canada
United States

International Markets

Argentina
Australia
Belarus
Brazil
Chile
China
Hong Kong SAR
India
Israel
Japan
Kazakhstan
Kyrgyzstan
Mexico
Peru
Russia
Singapore
South Africa
South Korea
Thailand
Turkey
Ukraine
Uruguay

Europe

North America

Canada
United States

International Markets

Argentina
Australia
Belarus
Brazil
Chile
China
Hong Kong SAR
India
Israel
Japan
Kazakhstan
Kyrgyzstan
Mexico
Peru
Russia
Singapore
South Africa
South Korea
Thailand
Turkey
Ukraine
Uruguay

Europe

Investors
News & Media

Our Company Show Submenu
We develop and produce medicines to help improve people’s lives.
Product Focus Show Submenu
Quality, accessibility, and innovation, without compromise
Patients & Caregivers Show Submenu
Our Impact Show Submenu
Teva is committed to making a positive impact by contributing to healthy communities and leading a responsible business.
Your Career Show Submenu
Dynamic. Diverse. Dedicated. Be Part of the Teva Team. At Teva, we strive to make a difference in the lives of people around the world each and every day.
Contact Us

Teva Pharmaceutical Industries Ltd.

Home
Search Results

Search Results

Search

Featured Stories

Access to medicine

Asthma

Biopharm

COVID-19

Disease Awareness

Diversity and inclusion

Environment

ESG

Europe

Generic Medicines

Global Operations

Leadership

Mental Health

Migraine

Multiple Chronic Conditions

Our People

Patient Focus

Quality

Regulatory Affairs

Research and Development

Social Impact

Working at Teva

Showing 2 of 2 results

Sort Order

FDA Approves Expanded Label for AZILECT® for Treatment Across All Stages of Parkinson’s Disease

Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) today announced the U.S. Food and Drug Administration (FDA) has expanded the indication for AZILECT ® (rasagiline tablets) from monotherapy and adjun...

FDA Approves Expanded Label for AZILECT® for Treatment Across All Stages of Parkinson’s Disease

At Teva, we strive to deliver quality medicines to patients around the world with integrity and ethical business practices. What we do is important, but how we do it is just as important. Learn more:

Teva Code of Conduct

Supplier Code of Conduct

Environmental, Social and Governance at Teva

All Corporate Governance & Policy Documents

Contact Us
Terms of Use
Social Media Guidelines
Teva api
Medis

Data Privacy
Pharmacovigilance Privacy Notice
Accessibility Statement
Cookie Settings

Follow us

Facebook
Twitter
Linkedin
Youtube

Copyright © 2022 Teva Pharmaceutical Industries Ltd.

You are about to leave the Teva Pharmaceuticals global website

The website you are about to access may be governed by different regional policies, regulations or advertising codes. Please be sure to read the privacy policy and terms of use of the websites that you visit.

Teva Pharmaceuticals is not responsible for the accuracy or compliance with laws of information on any third party websites.

Do you wish to proceed?